- Home
- ZCMD vs GLTO Comparison
ZCMD vs GLTO Comparison
Compare ZCMD & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZCMD
- GLTO
- Stock Information
- Founded
- ZCMD 2012
- GLTO 2011
- Country
- ZCMD China
- GLTO Denmark
- Employees
- ZCMD N/A
- GLTO N/A
- Industry
- ZCMD Other Consumer Services
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- ZCMD Real Estate
- GLTO Health Care
- Exchange
- ZCMD Nasdaq
- GLTO Nasdaq
- Market Cap
- ZCMD 29.2M
- GLTO 23.7M
- IPO Year
- ZCMD 2020
- GLTO 2020
- Fundamental
- Price
- ZCMD N/A
- GLTO $10.65
- Analyst Decision
- ZCMD
- GLTO Buy
- Analyst Count
- ZCMD 0
- GLTO 1
- Target Price
- ZCMD N/A
- GLTO $10.00
- AVG Volume (30 Days)
- ZCMD 28.1K
- GLTO 6.9M
- Earning Date
- ZCMD 01-01-0001
- GLTO 10-31-2025
- Dividend Yield
- ZCMD N/A
- GLTO N/A
- EPS Growth
- ZCMD N/A
- GLTO N/A
- EPS
- ZCMD N/A
- GLTO N/A
- Revenue
- ZCMD $13,117,523.00
- GLTO N/A
- Revenue This Year
- ZCMD N/A
- GLTO N/A
- Revenue Next Year
- ZCMD N/A
- GLTO N/A
- P/E Ratio
- ZCMD N/A
- GLTO N/A
- Revenue Growth
- ZCMD N/A
- GLTO N/A
- 52 Week Low
- ZCMD $0.86
- GLTO $2.01
- 52 Week High
- ZCMD $2.50
- GLTO $31.70
- Technical
- Relative Strength Index (RSI)
- ZCMD 58.04
- GLTO 64.47
- Support Level
- ZCMD $1.10
- GLTO $3.64
- Resistance Level
- ZCMD $1.30
- GLTO $31.70
- Average True Range (ATR)
- ZCMD 0.06
- GLTO 1.56
- MACD
- ZCMD 0.01
- GLTO 1.00
- Stochastic Oscillator
- ZCMD 54.35
- GLTO 28.83
About ZCMD Zhongchao Inc.
ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.